Emerging immunological drugs for chronic lymphocytic leukemia

Bibliography

• Hallek M, Cheson D, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–56
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Dreyling M, Robak T, et al. Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(Suppl 6):vi 50–4
   Google Scholar
• Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998;338:1506–14
   PubMed Web of Science ®Google Scholar
• Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079–88
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–74
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756–65
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): Final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood 2014;124:abstract 9
   Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with cll and coexisting conditions. N Engl J Med 2014;370:1101–10
   PubMed Web of Science ®Google Scholar
• Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet 2015;385:1873–83
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9–29
   PubMed Web of Science ®Google Scholar
• Redaelli A, Laskin BL, Stephens JM, et al. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care 2004;13:279–67
   PubMed Web of Science ®Google Scholar
• D’Souza P, Walker G. Spotlight on chronic lymphocytic leukemia: a Pharma Matters report. Drugs Today (Barc) 2014;50:485–501
   PubMed Web of Science ®Google Scholar
• Robak T. Rituximab for chronic lymphocytic leukemia. Expert Opin Biol Ther 2012;12:503–15
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010;47:115–23
   PubMed Web of Science ®Google Scholar
• Abrisqueta P, Villamor N, Terol MJ, et al. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood 2013;122:3951–9
   PubMed Web of Science ®Google Scholar
• Hornberger J, Reyes C, Shewade A, et al. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia. Leuk Lymphoma 2012;53:225–34
   PubMed Web of Science ®Google Scholar
• Robak T. Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. Curr Opin Mol Ther 2008;10:294–309
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749–55
   PubMed Web of Science ®Google Scholar
• van Oers MHJ, Kuliczkowski K, Smolej L, et al. Ofatumumab (ofa) maintenance prolongs PFS in relapsed CLL: prolong study interim analysis results. Blood (ASH Annual Meeting Abstracts) 2014;124:abstract 21
   Web of Science ®Google Scholar
• Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther 2013;12:2031–42
   PubMed Web of Science ®Google Scholar
• Robak T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs 2009;10:588–96
   PubMed Web of Science ®Google Scholar
• Patz M, Isaeva P, Forcob N, et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol 2011;152:295–306
   PubMed Web of Science ®Google Scholar
• Bologna L, Gotti E, Manganini M, et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011;186:3762–9
   PubMed Web of Science ®Google Scholar
• Salles G, Morschhauser F, Lamy T, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 2012;119:5126–32
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in. Leukemia 2013;27:1172–4
   PubMed Web of Science ®Google Scholar
• Flinn I, Brunvand M, Dyer MJS, et al. Preliminary results of a Phase 1b study (GP28331) combining GDC-0199 (ABT-199) and obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 2014;124:abstract 4687
   Google Scholar
• Cameron F, McCormack PL. Obinutuzumab: first global approval. Drugs 2014;74:147–54
   PubMed Web of Science ®Google Scholar
• Reyes C, Gazauskas G, Becker U, et al. Cost-effectiveness analysis of obinutuzumab versus ofatumumab for previously untreated chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2014;124:abstract 1324
   Google Scholar
• Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554–61
   PubMed Web of Science ®Google Scholar
• Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European study group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol 1997;15:1567–74
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27:3994–4001
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Gritti G, Laurenti L, et al. An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients. Br J Haematol 2012;156:481–9
   PubMed Web of Science ®Google Scholar
• Geisler CH, van T’ Veer MB, Jurlander J, et al. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. Blood 2014;123:3255–62
   PubMed Web of Science ®Google Scholar
• Frankfurt O, Ma S, Gordon L, et al. Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes. Leuk Lymphoma 2015;56:315–23
   PubMed Web of Science ®Google Scholar
• Ma S, Rosen ST, Frankfurt O, et al. A Phase 2 study of alemtuzumab-ofatumumab (A+O) combination in patients with previously untreated chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2014;124:abstract 4686
   Web of Science ®Google Scholar
• Schweighofer CD, Ritgen M, Eichhorst BF, et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol 2009;144:95–8
   PubMed Web of Science ®Google Scholar
• Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European study group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol 1997;15:1567–74
   PubMed Web of Science ®Google Scholar
• Robak T. New horizons in the treatment of chronic lymphocytic leukemia. Acta Haematol Pol 2014;45:122–31
   Google Scholar
• Buggy JJ, Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol 2012;31:119–32
   PubMed Web of Science ®Google Scholar
• Robak T, Robak E. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. Expert Opin Investig Drugs 2012;21:921–47
   PubMed Web of Science ®Google Scholar
• Garber K. Kinase inhibitors over achieve in CLL Nat Rev Drug Discov 2014;13:162–4
   Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010;107:13075–80
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32–42
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 2015;125:2497–506
   PubMed Web of Science ®Google Scholar
• O’Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014;15:48–58
   PubMed Web of Science ®Google Scholar
• Farooqui MZ, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol 2015;16:169–76
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371:213–23
   PubMed Web of Science ®Google Scholar
• Coutre A, O’Brien S, Byrd JC, et al. Safety and efficacy of ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who have undergone prior allogeneic stem cell transplant. Blood (ASH Annual Meeting Abstracts) 2014;124:abstract 4697
   Google Scholar
• Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2014;15:1090–9
   PubMed Web of Science ®Google Scholar
• Jaglowski SM, Jones JA, Flynn JM, et al. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. ASCO Meeting Abstracts 2012;30(Suppl 15):abstract 6508
   Google Scholar
• O’Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014;15:48–58
   PubMed Web of Science ®Google Scholar
• Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014;370:2286–94
   PubMed Web of Science ®Google Scholar
• Cheng S, Guo A, Lu P, et al. Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. Leukemia 2014;10.1038/leu.2014.263
   Web of Science ®Google Scholar
• Liu TM, Ling Y, Woyach JA, et al. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood 2015;125:284–95
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL- 101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010;116:2078–88
   PubMed Web of Science ®Google Scholar
• Awan FT, Byrd JC. New strategies in chronic lymphocytic leukemia: shifting treatment paradigms. Clin Cancer Res 2014;20:5869–74
   PubMed Web of Science ®Google Scholar
• Markham A. Idelalisib: first global approval. Drugs 2014;74:1701–7
   PubMed Web of Science ®Google Scholar
• Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014;123:3390–7
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Lamanna N, Kipps TJ, et al. A Phase 2 Study of Idelalisib Monotherapy in Previously Untreated Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Blood(ASH Annual Meeting Abstracts) 2014;124:abstract 1986
   Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370:997–1007
   PubMed Web of Science ®Google Scholar
• Sharman JP, Coutre SE, Furman RR, et al. Second interim analysis of a phase 3 study of idelalisib (ZYDELIG®) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors. Blood (ASH Annual Meeting Abstracts) 2014;124:abstract 330
   Google Scholar
• Acebes-Huerta A, Huergo-Zapico L, Gonzalez-Rodriguez AP, et al. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. Biomed Res Int 2014;2014:265840
   PubMed Web of Science ®Google Scholar
• Sher T, Miller KC, Lawrence D, et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma 2010;51:85–8
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24:5343–9
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291–7
   PubMed Web of Science ®Google Scholar
• James DF, Werner L, Brown JR, et al. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol 2014;32:2067–73
   PubMed Web of Science ®Google Scholar
• Thompson PA, Keating MJ, Hinojosa C, et al. Lenalidomide and rituximab in combination as initial treatment of chronic lymphocytic leukemia: initial results of a phase II study. Blood (ASH Annual Meeting Abstracts) 2014;124:abstract1988
   Google Scholar
• Chen CI, Bergsagel PL, Paul H, et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol 2011;29:1175–81
   PubMed Web of Science ®Google Scholar
• Badoux XC, Keating MJ, Wen S, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 2011;118:3489–98
   PubMed Web of Science ®Google Scholar
• Mato AR, Foon KA, Feldman T, et al. A Phase II Study of the Combination of FCR-lite and lenalidomide followed by lenalidomide maintenance in front-line CLL: The FCR Regimen. Blood (ASH Annual Meeting Abstracts) 2014;124:abstract 4678
   Google Scholar
• Costa LJ, Fanning SR, Stephenson JJr, et al. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Leuk Lymphoma 2015;56:645–9
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Bahlo J, Fink AM, et al. Good tolerance of lenalidomide maintenance therapy in patients with high risk profile chronic lymphocytic leukemia (CLL) after Frontline chemoimmunotherapy: preliminary safety overview of the CLLM1 trial of the German CLL Study Group (GCLLSG). Blood (ASH Annual Meeting Abstracts) 2014;124:abstract 4699
   Google Scholar
• Roberts AW, Ma S, Brander DM, et al. Determination of recommended phase 2 dose of venetoclax (ABT-199 (GDC-0199) combined with rituximab (R) in patients with relapsed/ refractory (R/R) chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2014;124:abstract 325
   Google Scholar
• Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 2011;15:e2–16
   PubMed Web of Science ®Google Scholar
• Ouillette P, Saiya-Cork K, Seymour E, et al. Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia. Clin Cancer Res 2013;19:2893–904
   PubMed Web of Science ®Google Scholar
• Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs 2011;25:13–25
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, de Vos S, Pohlman BL, et al. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res 2012;18:1395–403
   PubMed Web of Science ®Google Scholar
• Cheney CM, Stephens DM, Mo X, et al. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. MAbs 2014;6:749–55
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma 2010;51:747–55
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Rossi EA, Stein R, et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 2009;113:1062–70
   PubMed Web of Science ®Google Scholar
• Kalaycio M, Negrea OG, Elstrom R, et al. Monotherapy with subcutaneous (SC) injections of low doses of humanized anti-CD20 Veltuzumab is active in chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2012;120:abstract 192
   Google Scholar
• Barrena S, Almeida J, Yunta M, et al. Aberrant expression of tetraspanin molecules in Bcell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia 2005;19:1376–83
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Yeh YY, Wang L, et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 2012;21:694–708
   PubMed Web of Science ®Google Scholar
• Robak T, Robak P. Anti-CD37 antibodies for chronic lymphocytic eukemia. Exp Opin Biol Ther 2014;14:651–61
   PubMed Web of Science ®Google Scholar
• Smolewski P, Robak P, Cebula-Obrzut B, et al. Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies. Eur J Cancer 2014;50:2677–84
   PubMed Web of Science ®Google Scholar
• Pagel JM, Spurgeon SE, Byrd JC, et al. Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients. Br J Haematol 2015;168:38–45
   PubMed Web of Science ®Google Scholar
• Robak T, Robak P, Smolewski P. TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs 2009;10:1383–90
   PubMed Web of Science ®Google Scholar
• Zhao X, Lapalombella R, Joshi T, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 2007;110:2569–77
   PubMed Web of Science ®Google Scholar
• Byrd JC, Pagel JM, Awan FT, et al. A Phase 1 study evaluating the safety and tolerability of otlertuzumab (TRU-016), an anti-CD37 mono-specific ADAPTIRTM therapeutic protein in chronic lymphocytic leukemia. Blood 2014;123:1302–8
   PubMed Web of Science ®Google Scholar
• Maddocks KJ, Pagel J, Byrd JC, et al. Phase 1b study of otlertuzumab (TRU-016), an Anti-CD37 ADAPTIRTM protein, in combination with rituximab in patients with chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2014;124:abstract 4671
   Google Scholar
• Robak T, Hellman A, Kloczko J, et al. Phase 2 study of otlertuzumab (TRU-016), an anti-CD37 ADAPTIRTM protein, in combination with bendamustine vs bendamustine alone in patients with relapsed chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2013;122:abstract 2860
   Web of Science ®Google Scholar
• Heider KH, Kiefer K, Zenz T. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood 2011;118:4159–68
   PubMed Web of Science ®Google Scholar
• Stephens DM, Beckwith KA, Cheney C, et al. BI 836826, a novel FC-engineered antibody in combination with phosphoinositide-3-kinase inhibitor for treatment of high risk chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 2014;124:abstract 4681
   Google Scholar
• Deckert J, Park PU, Chicklas S, et al. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood 2013;122:3500–10
   PubMed Web of Science ®Google Scholar
• Beckwith KA, Frissora FW, Stefanovski MR, et al. The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia 2014;28:1501–10
   PubMed Web of Science ®Google Scholar
• Katz BZ, Herishanu Y. Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond. Leuk Lymphoma 2014;55:999–1006
   PubMed Web of Science ®Google Scholar
• Awan FT, Lapalombella R, Trotta R, et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 2010;115:1204–13
   PubMed Web of Science ®Google Scholar
• Zalevsky J, Leung IW, Karki S, et al. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood 2009;113:3735–43
   PubMed Web of Science ®Google Scholar
• Woyach JA, Avan F, Flinn IW, et al. Final results of a phase i study of the Fc engineered CD19 antibody XmAb®5574 (MOR00208) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Blood (ASH Annual Meeting Abstracts) 2012;120:abstract 2894
   Google Scholar
• Matlawska-Wasowska K, Ward E, Stevens S, et al. Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies. Leukemia 2013;27:1263–74
   PubMed Web of Science ®Google Scholar
• Ward E, Mittereder N, Kuta E, et al. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol 2011;155:426–37
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Hamadani M, Fanale MA, et al. Safety profile and clinical response to medi-551, a humanized monoclonal anti-cd19, in a phase 1/2 study in adults with relapsed or refractory advanced B-cell malignancies. Blood (ASH Annual Meeting Abstracts) 2013;122:abstract 1810
   Google Scholar
• Yazawa N, Hamaguchi Y, Poe JC, Tedder TF. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci USA 2005;102:15178–83
   PubMed Web of Science ®Google Scholar
• Breton CS, Nahimana A, Aubry D, et al. A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies. J Hematol Oncol 2014;7:33
   PubMed Web of Science ®Google Scholar
• Blanc V, Bousseau A, Caron A, et al. SAR3419: An Anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res 2011;17:6448–58
   PubMed Web of Science ®Google Scholar
• Ribrag V, Dupuis J, Tilly H, et al. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 2014;20:213–20
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Bargou R, Ruttinger D, et al. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma 2009;50:886–91
   PubMed Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2014;16(1):57–66
   PubMed Web of Science ®Google Scholar
• Cesano A, Gayko U. CD22 as a target of passive immunotherapy. Semin Oncol 2003;30:253–7
   PubMed Web of Science ®Google Scholar
• Moyron-Quiroz JE, Partida-Sánchez S, Donís-Hernández R, et al. Expression and function of CD22, a B-cell restricted molecule. Scand J Immunol 2002;55:343–51
   PubMed Web of Science ®Google Scholar
• Sullivan-Chang L, O’Donnell RT, Tuscano JM. Targeting CD22 in B-cell malignancies: current status and clinical outlook. BioDrugs 2013;27:293–304
   PubMed Web of Science ®Google Scholar
• Weldon JE, Xiang L, Chertov O, et al. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 2009;113:3792–800
   PubMed Web of Science ®Google Scholar
• Pathan NI, Chu P, Hariharan K, et al. Mediation of apoptosis by and anti-tumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood 2008;111:1594–602
   PubMed Web of Science ®Google Scholar
• Byrd JC, O’Brien S, Flinn IW, et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2007;13:4448–55
   PubMed Web of Science ®Google Scholar
• Byrd JC, Kipps TJ, Flinn IW, et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Br J Haematol 2010;115:489–95
   Google Scholar
• Awan FT, Hillmen P, Hellmann A, et al. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. Br J Haematol 2014;167:466–77
   PubMed Web of Science ®Google Scholar
• Stein R, Mattes MJ, Cardillo TM, et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res 2007;13(18 Pt 2):5556s–63s
   PubMed Web of Science ®Google Scholar
• (1):Smith MRJin F, Joshi I. Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-κB dependent human transformed follicular lymphoma cell line. Br J Haematol 2014;165:151–3
   PubMed Web of Science ®Google Scholar
• Hassan SB, Sørensen JF, Olsen BN, Pedersen AE. Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacol Immunotoxicol 2014;36:96–104
   PubMed Web of Science ®Google Scholar
• Law CL, Gordon KA, Collier J. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005;65:8331–8
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Gowda A, Joshi T, et al. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br J Haematol 2009;144:848–55
   PubMed Web of Science ®Google Scholar
• Furman RR, Forero-Torres A, Shustov A, Drachman JG. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2010;51:228–35
   PubMed Web of Science ®Google Scholar
• Luqman M, Klabunde S, Lin K, et al. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 2008;112:711–20
   PubMed Web of Science ®Google Scholar
• Luqman M, Klabunde S, Lin K, et al. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 2008;112:711–20
   PubMed Web of Science ®Google Scholar
• Byrd JC, Kipps TJ, Flinn IW, et al. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma 2012;53:2136–42
   PubMed Web of Science ®Google Scholar
• Khagi Y, Mark TM. Potential role of daratumumab in the treatment of multiple myeloma. Onco Targets Ther 2014;7:1095–100
   PubMed Web of Science ®Google Scholar
• Matas-Céspedes A, Vidal-Crespo A, Rodriguez V, et al. Daratumumab, a novel anti-CD38 Monoclonal antibody shows anti-tumor activity in CLL and hampers leukemia-microenvironment interactions. Blood 2014;124:abstract 4680
   Google Scholar
• Matas-Céspedes A, Crespo AV, Rodriguez V, et al. Daratumumab, a novel human anti-CD38 monoclonal antibody shows anti-tumor activity in mouse models of MCL, FL and CLL. Blood (ASH Annual Meeting Abstracts) 2013;122:abstract 378
   Google Scholar
• Fegan C, Bagshawe J, Salles G, et al. The Bruton’s tyrosine kinase (BTK) inhibitor ONO-4059: promising single agent activity and well tolerated in patients with high risk chronic lymphocytic leukaemia (CLL). Blood (ASH Annual Meeting Abstracts) 2014;124:abstract 3328
   Google Scholar
• Brown JR, Sharman JP, Harb WA, et al. Phase Ib trial of AVL-292, a covalent inhibitor of Bruton’s tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL). J Clin Oncol 2012;30(Suppl):abstract 8032
   Google Scholar
• Winkler DG, Faia KL, DiNitto JP, et al. PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol 2013;20:1364–74
   PubMed Web of Science ®Google Scholar
• Dong S, Guinn D, Dubovsky JA, et al. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood 2014;124:3583–6
   PubMed Web of Science ®Google Scholar
• Porcu P, Flinn I, Kahl BS, et al. Clinical activity of duvelisib (IPI-145), a phosphoinositide-3-kinase-δ,γ inhibitor, in patients previously treated with ibrutinib. Blood 2014;124:3335
   Web of Science ®Google Scholar
• O’Brien S, Patel M, Kahl BS, et al. Duvelisib (IPI-145), a PI3K-δ,γ inhibitor, is clinically active in patients with relapsed/refractory chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 2014;124:abstract 3334
   Web of Science ®Google Scholar
• Kater AP, Tonino SH, Kersten MJ, et al. Interim analysis of dose-escalation stage of a phase 1b study evaluating safety and pharmacology of GS-9820, a second-generation, selective, PI3Kd-Inhibitor in recurrent lymphoid malignancies. Blood (ASH Annual Meeting Abstracts) 2013;122:abstract 2881
   Web of Science ®Google Scholar
• Lonetti A, Antunes IL, Chiarini F, et al. Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia. Leukemia 2014;28:1196–206
   PubMed Web of Science ®Google Scholar
• Folkes AJ, Ahmadi K, Alderton WK, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008;51:5522–32
   PubMed Web of Science ®Google Scholar
• Dail M, Wong J, Lawrence J, et al. Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. Nature 2014;513:512–16
   PubMed Web of Science ®Google Scholar
• Anderson MA, Huang D, Roberts A. Targeting BCL2 for thetreatment of lymphoid malignancies. Semin Hematol 2014;51:219–27
   PubMed Web of Science ®Google Scholar
• Vogler M, Dinsdale D, Dyer MJ, Cohen GM. ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br J Haematol 2013;163:139–42
   PubMed Web of Science ®Google Scholar
• Seymour JF, Davids MS, Pagel JM, et al. Bcl-2 inhibitor ABT-199 (GDC- 0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Blood 2013;122:abstract 872
   Web of Science ®Google Scholar
• Salles GA, Boyd TE, Morschhauser F, et al. Preliminary results of a phase 1b study (GO28440) combining GDC-0199 (ABT-199) with bendamustine/rituximab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia. Blood 2014;124:abstract 3337
   Web of Science ®Google Scholar
• Paoluzzi L, Gonen M, Bhagat G, et al. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 2008;112:2906–16
   PubMed Web of Science ®Google Scholar
• Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable bcl-2 family inhibitor. Cancer Res 2008;68:3421–8
   PubMed Web of Science ®Google Scholar
• Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30:488–96
   PubMed Web of Science ®Google Scholar
• Davids MS, Letai A, Brown JR. Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leuk Lymphoma 2013;54:1823–5
   PubMed Web of Science ®Google Scholar
• Vogler M, Dinsdale D, Dyer MJ, Cohen GM. ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br J Haematol 2013;163:139–42
   PubMed Web of Science ®Google Scholar
• Ng SY, Davis MS. Selective BCL2 inhibition to treat chronic lymphocytic leukemia and non-Hodgki lymphoma. Clin Adv Hematol Oncol 2014;12:224–9
   PubMedGoogle Scholar
• Seymour JF, Davids MS, Anderson MA, et al. The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed/refractory chronic lymphocytic leukemia: interim results of a phase I first-in-human study. Blood (ASH Annual Meeting Abstracts) 2012;120:abstract 3923
   Google Scholar
• Seymour JF, Davids MS, Pagel JM, et al. Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). J Clin Oncol 2013;31(Suppl):abstract 7018
   Google Scholar
• Roberts AW, Man S, Brander DM, et al. Determination of recommended phase 2 dose of ABT-199 (GDC-0199) combined with rituximab (R) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Blood 2014;124:abstract 325
   Google Scholar
• Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013;121:1612–21
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427–37
   PubMed Web of Science ®Google Scholar
• Motta M, Rassenti L, Shelvin BJ, et al. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 2005;19:1788–93
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677–704
   PubMed Web of Science ®Google Scholar
• Grzywnowicz M, Karabon L, Karczmarczyk A, et al. The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia. Leuk Lymphoma 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Callahan MK, Wolchok JD. At the bedside: CTLA-4– and PD-1–blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013;94:41–53
   PubMed Web of Science ®Google Scholar
• Grzywnowicz M, Zaleska J, Mertens D, et al. Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. PLoS ONE 2012;7:e35178
   PubMed Web of Science ®Google Scholar
• Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014;15:69–77
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015;372:311–19
   PubMed Web of Science ®Google Scholar
• Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14:3044–51
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, et al. Chimeric antigenreceptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725–33
   PubMed Web of Science ®Google Scholar
• Porter DL, Frey NV, Loren AW, et al. A phase II, dose-optimization trial of autologous T cells genetically engineered to express anti-CD19 chimeric antigen receptor (CART-19) in patients with relapsed or refractory (r/r) CD19+ chronic lymphocytic leukemia (CLL). J Clin Oncol 2013;31(Suppl):abstract TPS7132
   Google Scholar
• Porter D, Kalos M, Frey NV, et al. Chimeric antigen receptor modified T cells directed against CD19 (CTL019 cells) have long-term persistence and induce durable responses in relapsed, refractory CLL. Blood 2013;122:abstract 4162
   Web of Science ®Google Scholar
• Beum PV, Peek EM, Lindorfer MA, et al. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J Immunol 2011;187:3438–47
   PubMed Web of Science ®Google Scholar
• Beurskens FJ, Lindorfer MA, Farooqui M, et al. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol 2012;188:3532–41
   PubMed Web of Science ®Google Scholar
• Beers SA, French RR, Chan HT, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010;115:5191–201
   PubMed Web of Science ®Google Scholar
• Dail M, Wong J, Lawrence J, et al. Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. Nature 2014;513:512–16
   PubMed Web of Science ®Google Scholar
• Beurskens FJ, Lindorfer MA, Farooqui M, et al. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol 2012;188:3532–41
   PubMed Web of Science ®Google Scholar